Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

Roschewski, Mark; S. Lionakis, Michail; P. Sharman, Jeff; Roswarski, Joseph; Goy, André; Monticelli, Massimiliano; Roshon, Michael; H. Wrzesinski, Stephen; V. Desai, Jigar; A. Zarakas, Marissa; Collen, Jacob; Rose, Keith; Hamdy, Ahmed; Izumi, Raquel; W. Wright, George; K. Chung, Kevin; Baselga, José; M. Staudt, Louis; H. Wilson, Wyndham

doi:10.1126/sciimmunol.abd0110

Public

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

Published in Science Immunology • Jun 5, 2020

Authors:

Mark Roschewski

Michail S. Lionakis

Jeff P. Sharman

Abstract

Patients with severe COVID-19 have a hyperinflammatory immune response suggestive of macrophage activation. Bruton tyrosine kinase (BTK) regulates macrophage signaling and activation. Acalabrutinib, a selective BTK inhibitor, was administered off-label to 19 patients hospitalized with severe COVID-1...

Subject

Bruton's tyrosine kinase

Medicine

Immunology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!